Enochian Stock Is Trading Higher On FDA Acceptance of Pre-IND Request For Hepatitis B Program

  • Enochian BioSciences Inc ENOB has announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection.
  • Written comments are expected this Fall.
  • The Pre-IND request was made based on promising data from a proof-of-concept study conducted in chimeric mice, considered by some scientific experts to be the ‘gold standard’ animal model to evaluate HBV cure, the company said in the press release.
  • Hepatitis B program is based on a mechanism of action called Hijack RNA that shows promise as a potential platform technology for coronaviruses (including the cause of COVID-19), influenza, and HBV, and are exploring its use against HIV.
  • Last month, the company acquired an exclusive license for a technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza. 
  • Price Action: ENOB shares are up 7.2% at $5.64 during the premarket session on the last check Monday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefshepatitis B
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!